Portal de investigação
IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus
Data de publicação:
Data Ahead of Print:
Autores da FMUP
Participantes de fora da FMUP
- Caron, B
- Abreu, MT
- Siegel, CA
- Panaccione, R
- Sands, BE
- Dignass, A
- Turner, D
- Dotan, I
- Hart, AL
- Ahuja, V
- Allez, M
- Ananthakrishnan, AN
- Ghosh, S
- Griffiths, AM
- Halfvarson, J
- Kaser, A
- Kotze, PG
- Koutroubakis, IE
- Lakatos, PL
- Levine, A
- Lewis, JD
- Mantzaris, GJ
- O'Morain, C
- Ran, ZH
- Reinisch, W
- Rogler, G
- Sachar, DB
- Siegmund, B
- Silverberg, MS
- Sood, A
- Spinelli, A
- Steinwurz, F
- Tysk, C
- Yamamoto-Furusho, JK
- Schreiber, S
- Rubin, DT
- Sandborn, WJ
- Danese, S
- Peyrin-Biroulet, L
Unidades de investigação
Abstract
BACKGROUND & AIMS: Clinical trials evaluating biologics and small molecules in patients with ulcerative colitis are predominantly excluding ulcerative proctitis. The objective of the Definition and endpoints for ulcerative PROCtitis in clinical TRIALs initiative was to develop consensus statements for definitions, inclusion criteria, and endpoints for the evaluation of ulcerative proctitis in adults. METHODS: Thirty-five international experts held a consensus meeting to define ulcerative proctitis, and the endpoints to use in clinical trials. Based on a systematic review of the literature, statements were generated, discussed, and approved by the working group participants using a modified Delphi method. Consensus was defined as at least 75% agreement among voters. RESULTS: The group agreed that the diagnosis of ulcerative proctitis should be made by ileocolonoscopy and confirmed by histopathology, with the exclusion of infections, drug-induced causes, radiation, trauma, and Crohn's disease. Ulcerative proctitis was defined as macroscopic extent of lesions limited to 15 cm distance from the anal verge in adults. Primary and secondary endpoints were identified to capture response of ulcerative proctitis to therapy. A combined clinical and endoscopic primary endpoint for the evaluation of ulcerative proctitis disease activity was proposed. Secondary endpoints that should be evaluated include endoscopic remission, histologic remission, mucosal healing, histologic endoscopic mucosal improvement, disability, fecal incontinence, urgency, constipation, and health-related quality of life. CONCLUSIONS: In response to the need for guidance on the design of clinical trials in patients with ulcerative proctitis, the Definition and end points for ulcerative PROCtitis in clinical TRIALs consensus provides recommendations on the definition and endpoints for ulcerative proctitis clinical trials.
Dados da publicação
- ISSN/ISSNe:
- 1542-7714, 1542-3565
- Tipo:
- Article
- Páginas:
- 2619-2619
- Link para outro recurso:
- www.scopus.com
Clinical Gastroenterology and Hepatology W.B. Saunders Ltd
Citações Recebidas na Web of Science: 7
Citações Recebidas na Scopus: 13
Documentos
- Não há documentos
Filiações
Keywords
- Ulcerative Proctitis; Definition; Consensus; Endpoint
Financiamento
Proyectos asociados
Gut microbiome and IBD therapy: an interplay?
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (GutIBD) . 2021
Iron deficiency and inflammatory bowel disease. Correlation with inflammation and Vitamin D status.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (IronIBD) . 2021
Looking 4WARD: The role of dipeptidyl peptidase 4 (DPP-4) in inflammatory bowel disease (IBD) as a novel biomarker for predicting disease activity and monitoring response to therapy in IBD patients.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (4WARD) . 2021
Isolated Ulceration of Crohn’s Anastomosis
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2021
Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2022
Therapeutic Drug Monitoring: An Emergent Approach in Inflammatory Bowel Disease
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2021
Contributo da endoscopia, biomarcadores e imagiologia na evolução clinica dos doentes com doença inflamatória intestinal
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2019
Citar a publicação
Caron B,Abreu MT,Siegel CA,Panaccione R,Sands BE,Dignass A,Turner D,Dotan I,Hart AL,Ahuja V,Allez M,Ananthakrishnan AN,Ghosh S,Griffiths AM,Halfvarson J,Kaser A,Kotze PG,Koutroubakis IE,Lakatos PL,Levine A,Lewis JD,Magro F,Mantzaris GJ,O'Morain C,Ran ZH,Reinisch W,Rogler G,Sachar DB,Siegmund B,Silverberg MS,Sood A,Spinelli A,Steinwurz F,Tysk C,Yamamoto JK,Schreiber S,Rubin DT,Sandborn WJ,Danese S,Peyrin L. IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. Clin. Gastroenterol. Hepatol. 2022. 20. (11):p. 2619-2619. IF:12,600. (1).
